Next-Generation Chimeric Antigen Receptor T-cells.
Publication/Presentation Date
12-15-2022
Abstract
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 years. CAR T-cell therapy significantly improved outcomes for patients with B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, recurrence and progression may occur after the initial response due to multiple mechanisms (Zeng and Zhang, 2022) [1]. Furthermore, CAR T-cell therapy is not broadly utilized in solid tumors due to various barriers. This review discusses the evolution of CAR T-cell therapies and how the "younger-generation" CAR T cells counteract these challenges to potentially broaden their applications in the future.
Volume
15
Issue
3
First Page
117
Last Page
121
ISSN
2589-0646
Published In/Presented At
Yi, D., Gergis, M., Hsu, J., Yang, Y., Bi, X., Aljurf, M., & Gergis, U. (2022). Next-Generation Chimeric Antigen Receptor T-cells. Hematology/oncology and stem cell therapy, 15(3), 117–121. https://doi.org/10.56875/2589-0646.1035
Disciplines
Medicine and Health Sciences
PubMedID
36537905
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article